'Keytruda' attempts at reimbursement for TNBC
By Whang, byung-woo | translator Hong, Ji Yeon
24.09.24 05:04:02
가나다라
0
Keytruda will likely be reconsidered for the 7th CDRC review of the HIRA in October
The KEYNOTE-522 study's overall survival (OS) data were presented at the ESMO congress
Whether the company will suggest making additional financial contribution draws attention
The industry watches whether Keytruda (pembrolizumab), which demonstrated treatment benefits in early triple-negative breast cancer, will pass the reimbursement hurdle.
As the Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) convenes in October, whether Keytruda will set a ground to expand 17 indications will be watched.
▲Product photo of Keytruda
According to the pharmaceutical industry, the HIRA will convene the 7th Cancer Disease Review Committee (CDRC) meeting on October 2nd. Currently, Imfinzi (durvalumab) and Jemperli (dostarlimab) are applying for reimbursement expansion. The review of Keytruda, which has applied for reimbursement of 17 indic
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)